Sangamo BioSciences (SGMO)

Company Description

Sangamo BioSciences is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase II clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. SGMO’s other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington’s disease and hemoglobinopathies such as beta-thalassemia and sickle cell anemia. SGMO’s core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. The company has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington’s disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation.

 

COMPANY ADDRESS
501 Canal Boulevard
Richmond, California 94804
United States

COMPANY PHONE
510-970-6000

COMPANY WEBSITE



Get BioInvest's perspective on Sangamo's CEO


Latest Company News

Sangamo Therapeutics (SGMO) Earns Daily News Impact Rating of 0.04 The Cerbat Gem - 5 hours ago Sangamo Therapeutics logo News headlines about Sangamo Therapeutics (NASDAQ:SGMO) have trended somewhat positive on Thursday, Alpha One reports. 66 institutional investors are raising stakes in Sangamo Therapeutics, Inc ... - Post Analyst Short Interest in Sangamo Therapeutics Inc (SGMO) Grows By 2.0% - Sports Perspectives [...]
Fri, Apr 28, 2017 12:45:00 AM, Continue reading at the source
Inside the Numbers for Sangamo Therapeutics, Inc. (NASDAQ:SGMO) The Standard - 11 hours ago Investors are constantly examining different company financial indicators to assess trading opportunities. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) presently has an EV or Enterprise Value of 235774. The EV is used to show how the market assigns value ... [...]
Thu, Apr 27, 2017 6:56:00 PM, Continue reading at the source
Investor Review: Focusing in on Shares of Sangamo Therapeutics Inc (SGMO) Searcy News - 12 hours ago Investors and Traders using technical analysis to study stocks may be looking at the ATR or Average True Range. Presently, Sangamo Therapeutics Inc (SGMO) has a 14-day ATR of 0.29. The Average True Range is an investor tool used to gauge stock ... [...]
Thu, Apr 27, 2017 5:48:00 PM, Continue reading at the source
Stock Returns: BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) versus Sangamo ... CML News - Apr 26, 2017 This is a snapshot to compare the stock returns for BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) versus Sangamo Therapeutics Inc (NASDAQ:SGMO) . The stock return points we compare look at the last three-months, six-months and twelve-months. [...]
Wed, Apr 26, 2017 10:18:00 PM, Continue reading at the source
Revenue Approximations Analysis: Tupperware Brands Corporation (TUP), Sangamo ... StockNewsJournal - Apr 26, 2017 Sangamo Therapeutics, Inc. (NASDAQ:SGMO), maintained return on investment for the last twelve months at -41.94, higher than what Reuters data shows regarding industry's average. [...]
Wed, Apr 26, 2017 1:52:00 PM, Continue reading at the source
Sangamo Announces The Retirement Of Its Founder And Genome Editing Pioneer ... PR Newswire (press release) - Apr 25, 2017 RICHMOND, Calif., April 25, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, today announced that its founder and Chairman Edward Lanphier is not standing for re-election as a director nominee ... [...]
Tue, Apr 25, 2017 8:03:00 PM, Continue reading at the source
Sangamo Therapeutics Announces Presentations at 2017 Annual meeting of the ... PR Newswire (press release) - Apr 24, 2017 RICHMOND, Calif., April 24, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced that data from the Company's therapeutic and research programs will be presented at the 20th Annual ... [...]
Mon, Apr 24, 2017 9:00:00 PM, Continue reading at the source
Sangamo Therapeutics Inc (SGMO) Stake Held by Fmr LLC BBNS - Apr 13, 2017 Sangamo Therapeutics logo FMR LLC continued to hold its stake in shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. An Inside Look at Trading Hot Stocks: Sangamo Therapeutics, Inc. (SGMO ... - Post Analyst [...]
Thu, Apr 13, 2017 12:14:00 PM, Continue reading at the source
Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-913 ... PR Newswire (press release) - Mar 1, 2017 RICHMOND, Calif., March 1, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that the U.S. [...]
Wed, Mar 01, 2017 1:33:00 PM, Continue reading at the source
Sangamo BioSciences Changes Name To Sangamo Therapeutics, Underscoring Focus ... PR Newswire (press release) - Jan 6, 2017 RICHMOND, Calif., Jan. 6, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announces that it has changed its corporate name, from "Sangamo BioSciences, Inc." to "Sangamo Therapeutics, Inc." ... [...]
Fri, Jan 06, 2017 1:06:00 PM, Continue reading at the source